Drug Profile

BMND 06

Alternative Names: BMND-06; BMND-09

Latest Information Update: 28 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Biomind Labs
Developer Albert Einstein Israelite Hospital; Biomind Labs
Class Anti-inflammatories; Antiparkinsonians; Obesity therapies; Phenethylamines; Phenyl ethers; Small molecules
Mechanism of Action Serotonin 5-HT2A receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 Apr 2025 No recent reports of development identified for phase-I development in Obesity in Canada
27 Nov 2023 Phase-I clinical trials in Parkinson's disease in Canada (unspecified route) prior to November 2023 (Biomind Labs pipeline, November 2023)
22 Sep 2023 Discontinued - Clinical-Phase-Unknown for Inflammation in Canada (unspecified route) (Biomind Labs pipeline, September 2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com